DCAL

Dishman Carbogen Amcis Share Price

₹217.53 -2.48 (-1.13%)

21 Nov, 2024 14:18

SIP TrendupStart SIP in DCAL

Start SIP

Performance

  • Low
  • ₹213
  • High
  • ₹225
  • 52 Week Low
  • ₹133
  • 52 Week High
  • ₹283
  • Open Price₹216
  • Previous Close₹220
  • Volume1,215,811

Investment Returns

  • Over 1 Month + 9.81%
  • Over 3 Month + 26.66%
  • Over 6 Month + 10.83%
  • Over 1 Year + 26.58%
SIP Lightning

Smart Investing Starts Here Start SIP with Dishman Carbogen Amcis for Steady Growth!

Invest Now

Dishman Carbogen Amcis Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -19.6
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 3,411
  • P/B Ratio
  • 0.6
  • Average True Range
  • 12.68
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.01
  • RSI
  • 63.46
  • MFI
  • 83.76

Dishman Carbogen Amcis Financials

Dishman Carbogen Amcis Technicals

EMA & SMA

Current Price
₹217.53
-2.48 (-1.13%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹195.16
  • 50 Day
  • ₹189.98
  • 100 Day
  • ₹188.91
  • 200 Day
  • ₹186.80

Resistance and Support

223.27 Pivot Speed
  • R3 245.02
  • R2 238.86
  • R1 229.43
  • S1 213.84
  • S2 207.68
  • S3 198.25

What's your outlook on Dishman Carbogen Amcis?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Dishman Carbogen Amcis Ltd. is a leading global contract research and manufacturing organization (CRMO) based in India, specializing in pharmaceutical and biotechnology services. The company focuses on providing high-quality, innovative solutions in API production and custom synthesis.

Dishman Carbogen Amcis has an operating revenue of Rs. 2,618.62 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of -5% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 16% and 11% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Dishman Carbogen Amcis Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-13 Quarterly Results
2024-05-30 Audited Results
2024-02-14 Quarterly Results
2023-11-08 Quarterly Results

Dishman Carbogen Amcis F&O

Dishman Carbogen Amcis Shareholding Pattern

59.32%
1.03%
8.18%
27.43%
4.04%

About Dishman Carbogen Amcis

  • NSE Symbol
  • DCAL
  • BSE Symbol
  • 540701
  • Global Managing Director
  • Mr. Arpit J Vyas
  • ISIN
  • INE385W01011

Similar Stocks to Dishman Carbogen Amcis

Dishman Carbogen Amcis FAQs

Dishman Carbogen Amcis share price is ₹217 As on 21 November, 2024 | 14:04

The Market Cap of Dishman Carbogen Amcis is ₹3410.5 Cr As on 21 November, 2024 | 14:04

The P/E ratio of Dishman Carbogen Amcis is -19.6 As on 21 November, 2024 | 14:04

The PB ratio of Dishman Carbogen Amcis is 0.6 As on 21 November, 2024 | 14:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23